Zsa Zsa Weerts

Dr. Zsa Zsa Weerts

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ZWZsa Zsa Weerts
Zsa Zsa Weerts
AMAd A.M. Masclee
Ad A.M. Masclee
BWBen J.M. Witteman
Ben J.M. Witteman
CCCees H.M. Clemens
Cees H.M. Clemens
Bjorn WinkensBjorn Winkens
Bjorn Winkens
DKDaniel Keszthelyi
Daniel Keszthelyi

14 August 2017 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
LVLisa Vork
Lisa Vork
ZWZsa Zsa Weerts
Zsa Zsa Weerts
ZMZlatan Mujagic
Zlatan Mujagic
JKJ. W. Kruimel
J. W. Kruimel
MHM. A. M. Hesselink
M. A. M. Hesselink
AMA. A. M. Masclee
A. A. M. Masclee

3 May 2021 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
JSJohanna T. W. Snijkers
Johanna T. W. Snijkers
WOWendy van Den Oever
Wendy van Den Oever
ZWZsa Zsa Weerts
Zsa Zsa Weerts
LVLisa Vork
Lisa Vork
ZMZlatan Mujagic
Zlatan Mujagic
DKDaniel Keszthelyi
Daniel Keszthelyi
Background: Self‐rating scales are frequently used to screen for anxiety and depression in patients with irritable bowel syndrome (IBS). Different cutoff values are recommended in literature, and guidelines have suggested the use of other screening instruments over time. The aim of this study was to assess the correlation between the most commonly used psychological screening instruments for anxiety and depression in IBS and to compare custom cutoff scores for these instruments.Methods: Irritable bowel syndrome patients (n = 192) completed several questionnaires including the Hospital Anxiety and Depression Scale (HADS, HADS‐A and HADS‐D subscale), Patient Health Questionnaire‐9 (PHQ‐9) and Generalized Anxiety Disorder‐7 (GAD‐7). Agreement at different cutoff points, for depressive and anxiety disorder, was assessed by use of the Gwet AC1 coefficient.Key Results: Hospital Anxiety and Depression Scale (HADS)‐D and PHQ‐9 scores, and HADS‐A and GAD‐7 scores showed high correlations (rs = 0.735 and rs = 0.805, respectively). For depressive disorder, a Gwet AC1 value of 0.829 was found when recommended cutoff points from literature were compared (PHQ‐9 cutoff ≥10, HADS‐D cutoff ≥8). For anxiety disorder, a Gwet AC1 value of 0.806 was found when recommended cutoff points from literature were compared (GAD‐7 cutoff ≥10, HADS‐A cutoff ≥8). Even higher agreements were found when higher HADS cutoff values were chosen, with impact on sensitivity and specificity.Conclusions & Inferences: Custom cutoff values deem the HADS subscales (HADS‐D and HADS‐A) concordant to PHQ‐9 and GAD‐7 scores. The choice of a cutoff value has substantial impact on sensitivity/specificity and is dependent on patient population, setting, and the purpose of use.

22 May 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
ZWZsa Zsa Weerts
Zsa Zsa Weerts
LVLisa Vork
Lisa Vork
ZMZlatan Mujagic
Zlatan Mujagic
DKDaniel Keszthelyi
Daniel Keszthelyi
MHMartine A. M. Hesselink
Martine A. M. Hesselink
AMAd A. M. Masclee
Ad A. M. Masclee
Background: Irritable bowel syndrome (IBS) is a brain‐gut disorder, of which the natural course varies between patients and is difficult to predict. This study aimed to evaluate symptom evolution over a 5‐year follow‐up period and to identify baseline predictors for symptom severity and quality of life (QoL) at follow‐up.Methods: Maastricht IBS cohort participants completed questionnaires upon inclusion regarding demographics and lifestyle, gastrointestinal (GI) symptoms, anxiety and depression, and QoL. The same questionnaires, in addition to others, were completed after 5 years. Rome criteria were confirmed face‐to‐face at initial enrollment and through telephonic interviews at follow‐up.Key Results: At a mean follow‐up of 4.7 years, 379 patients were approached of whom 203 (53.7%) responded. Of these, 161 were reached by telephone and analyzed; 49 (30.4%) did not fulfill the Rome III criteria at follow‐up and had lower levels of GI symptoms and GI‐specific anxiety compared to those remaining Rome III‐positive (P < 0.001). However, Rome III‐negative patients had comparable levels of QoL and life satisfaction, comorbid anxiety and depression, work absenteeism, and impaired productivity. No baseline predictors were found for being Rome III‐positive or Rome III‐negative. However, greater age and lower baseline physical QoL predicted lower physical QoL at follow‐up (P < 0.005 andP < 0.01, respectively), while lower baseline mental QoL predicted lower mental QoL at follow‐up (P = 0.005). Additionally, higher anxiety and depression scores at follow‐up were associated with lower QoL and life satisfaction at follow‐up (P < 0.001).Conclusions and Inferences: Long‐term QoL and general well‐being might depend on concurrent psychological symptoms, rather than GI symptom improvement.

8 September 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ABAbraham Beckers
Abraham Beckers
ZWZsa Zsa Weerts
Zsa Zsa Weerts
ZHZ. Helyes
Z. Helyes
AMA. A. M. Masclee
A. A. M. Masclee
DKDaniel Keszthelyi
Daniel Keszthelyi

3 July 2017 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
ZMZlatan Mujagic
Zlatan Mujagic
DJD. M. A. E. Jonkers
D. M. A. E. Jonkers
SLS. Ludidi
S. Ludidi
DKD. Keszthelyi
D. Keszthelyi
MHM. A. Hesselink
M. A. Hesselink
AMA. A. M. Masclee
A. A. M. Masclee